Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2023 Q2- Text added to 2023 Q3
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. sophomore Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. sophomore Avg
|
New words:
antibody, antitumor, blood, boost, characterization, cohort, cold, component, contacting, correlative, cycle, cytokine, cytotoxicity, deep, Department, depicted, domain, draining, East, effector, elevation, enzyme, fourth, graphic, Gynecologic, Gynecology, highest, hot, immunosuppression, immunosuppressive, injection, labor, led, lessen, liver, lymph, main, median, medium, microenvironment, Middle, oRepeated, pathway, premium, pretreated, Professor, progenitor, rationale, Rectal, relapse, renovate, renovation, repayment, retainage, role, SASP, scanning, shown, skin, strongly, subcutaneously, syndrome, TIS, TOBITM, traffic, trafficking, transitory, turning, undergo, underwent, unique, upgraded, Women
Valuein 2023 Q2 filing- Value in 2023 Q3 filing
Original filings
Filing view